Most People With HIV Are Willing to Switch to Long-Acting Treatment
A recent study published in the journal AIDS indicates that 70% of people living with HIV are open to switching from daily oral medication to long-acting injectable regimens. While these treatments offer convenience and improved adherence, researchers note that accessibility and affordability remain significant barriers to widespread adoption.
Why it matters
Long-acting therapies represent a major shift in HIV management, potentially improving quality of life and treatment outcomes for millions of patients.
70% of study participants said they would like to use longer-acting regimens instead of daily pills.
More than two thirds people currently taking daily pills for HIV treatment would be willing to switch to a long-acting regimen, according to a systematic review and meta-analysis published in the journal AIDS . Willingness varied across studies, however, and most were conducted in high-income countries.
"Given that long-acting regimen preferences are highly individualized and difficult to predict, eligible individuals should be informed about this option where the clinical and contextual situation allows," the review authors wrote.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in